keyword
MENU ▼
Read by QxMD icon Read
search

postmenopause

keyword
https://www.readbyqxmd.com/read/28545269/-risk-factors-of-endometriosis-associated-ovarian-carcinoma-in-women-aged-45-years-and-older
#1
Z X He, S Wang, Z F Li, L Zhu, J H Leng, J H Lang
Obiective: To explore the risk factors of endometriosis-associated ovarian cancer (EAOC) in women with ovarian endometriosis aged 45 years and older in China. Methods: The medical records of total 1 038 women aged 45 years and older with a surgicopathological diagnosis of ovarian endometriosis treated at Peking Union Medical College Hospital from December 1994 to December 2014 were reviewed. Histology evaluation determined ovarian endometriosis with (n=30) or without (n=1 008) ovarian cancer. Results: (1) There were 30 (2...
May 25, 2017: Zhonghua Fu Chan Ke za Zhi
https://www.readbyqxmd.com/read/28544644/%C3%AE-cell-function-in-postmenopausal-women-with-isolated-postchallenge-hyperglycemia
#2
Chii-Min Hwu, Yi-Chun Lin, Kuan-Hung Lin
BACKGROUND: Isolated postchallenge hyperglycemia (IPH) is an early stage of type 2 diabetes mellitus (T2DM) with fasting glucose < 126 mg/dL and 2 h glucose ≥ 200 mg/dL. Observations of insulin secretion profile in subjects with IPH may provide insight to the pathogenesis of T2DM in older women. METHODS: We recruited 555 naturally postmenopausal women without a history of T2DM for this study. All participants received a 75 g oral glucose tolerance test to examine if they had IPH...
May 22, 2017: Journal of Diabetes
https://www.readbyqxmd.com/read/28543940/greater-gains-in-spine-and-hip-strength-for-romosozumab-compared-to-teriparatide-in-postmenopausal-women-with-low-bone-mass
#3
T M Keaveny, D B Crittenden, M A Bolognese, H K Genant, K Engelke, B Oliveri, J P Brown, B L Langdahl, C Yan, A Grauer, C Libanati
Romosozumab is a monoclonal antibody that inhibits sclerostin and has been shown to reduce the risk of fractures within 12 months. In a Phase II, randomized, placebo-controlled clinical trial of treatment-naïve postmenopausal women with low bone mass, romosozumab increased BMD at the hip and spine by the dual effect of increasing bone formation and decreasing bone resorption. In a substudy of that trial, which included placebo and teriparatide arms, here we investigated whether those observed increases in BMD also resulted in improvements in estimated strength, as assessed by finite element analysis...
May 25, 2017: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/28541645/raloxifene-plus-antipsychotics-versus-placebo-plus-antipsychotics-in-severely-ill-decompensated-postmenopausal-women-with-schizophrenia-or-schizoaffective-disorder-a-randomized-controlled-trial
#4
Mark Weiser, Linda Levi, Shimon Burshtein, Michal Hagin, Valentin P Matei, Delia Podea, Ioana Micluția, Alexandru Tiugan, Bogdan Păcală, Iosif Gabos Grecu, Adam Noy, Daisy Zamora, John M Davis
OBJECTIVE: Several single-center studies have found raloxifene, an estrogen agonist, to be effective in ameliorating symptoms of schizophrenia in stable patients as augmentation of antipsychotics. This multicenter study assessed whether raloxifene plus antipsychotic treatment, in comparison to placebo plus antipsychotics, improves symptoms or cognition in severely ill decompensated schizophrenia patients. METHODS: In this 16-week, double-blind, randomized, placebo-controlled study, 200 severely ill, decompensated postmenopausal women who met DSM-IV-TR criteria for schizophrenia or schizoaffective disorder were recruited from January 2011 to December 2012 and were randomized to receive either raloxifene 120 mg/d plus antipsychotics or placebo plus antipsychotics...
May 23, 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28540770/transdermal-estrogens-in-the-changing-landscape-of-hormone-replacement-therapy
#5
Keli L Beck, Michelle C Anderson, Julienne K Kirk
Views and clinical practice on hormone replacement therapy (HRT) for postmenopausal women have varied widely over the last several decades. The 1990s showed a dramatic decline in prescribing and only recently are prescription rates increasing again. Use of HRT is first line for women suffering from the symptoms of menopause. For a certain population of postmenopausal women, HRT is recommended for prevention of fracture. More consideration is being given to patient risk factors, side effects, and formulations available...
May 25, 2017: Postgraduate Medicine
https://www.readbyqxmd.com/read/28540402/a-qualitative-evaluation-of-breast-cancer-survivors-acceptance-of-and-preferences-for-consumer-wearable-technology-activity-trackers
#6
Nga H Nguyen, Nyssa T Hadgraft, Melissa M Moore, Dori E Rosenberg, Chris Lynch, Marina M Reeves, Brigid M Lynch
BACKGROUND: Physical inactivity and sedentary behaviour are common amongst breast cancer survivors. These behaviours are associated with an increased risk of comorbidities such as heart disease, diabetes and other cancers. Commercially available, wearable activity trackers (WATs) have potential utility as behavioural interventions to increase physical activity and reduce sedentary behaviour within this population. PURPOSE: The purpose of the study is to explore the acceptability and usability of consumer WAT amongst postmenopausal breast cancer survivors...
May 24, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28540087/elevated-cardiovascular-risks-among-postmenopausal-women-a-community-based-case-control-study-from-nepal
#7
Bashu Dev Pardhe, Sumitra Ghimire, Jyotsna Shakya, Sabala Pathak, Shreena Shakya, Anjeela Bhetwal, Puspa Raj Khanal, Narayan Prasad Parajuli
Cardiovascular disease (CVD) is one of the leading causes of death worldwide which is more prevalent in women after menopause. Hormonal changes associated with menopause are accountable for dyslipidemic pattern that causes CVD and associated complications. Therefore, the present study was commenced to compare the lipid profile in pre- and postmenopausal women. A descriptive cross-sectional study was conducted at Manmohan Memorial Institute of Health Sciences (MMIHS) from February 2016 to July 2016. A total of 260 fasting samples were collected from healthy women, 130 from premenopausal and 130 from postmenopausal women, and analyzed for Total Cholesterol (TC), Triacylglycerol (TAG), High Density Lipoprotein Cholesterol (HDL-C), and Low Density Lipoprotein Cholesterol (LDL-C) as per the guideline provided by the reagent manufacturer (Human, Germany)...
2017: Biochemistry Research International
https://www.readbyqxmd.com/read/28539823/association-between-sarcopenia-and-hearing-thresholds-in-postmenopausal-women
#8
Seok Hui Kang, Da Jung Jung, Kyu Hyang Cho, Jong Won Park, Kyu-Yup Lee, Jun Young Do
Background: Given the association between metabolic disturbance and sarcopenia, sarcopenia may be intrinsically associated with the prevalence of HL. However, few studies describe the association between sarcopenia and HL. The aim of this study was to evaluate the clinical association between sarcopenia and HL in postmenopausal Korean women. Patients and Methods: A total of 4,038 women were ultimately included in this study. All participants were postmenopausal. Participants were divided into two groups based on criteria from the Foundation for the National Institute of Health Sarcopenia Project: a normal group (sarcopenia index ≥ 0...
2017: International Journal of Medical Sciences
https://www.readbyqxmd.com/read/28539177/relationship-between-changes-in-vulvar-vaginal-atrophy-and-changes-in-sexual-functioning
#9
JoAnn V Pinkerton, Andrew G Bushmakin, Barry S Komm, Lucy Abraham
OBJECTIVE: Conjugated estrogens/bazedoxifene (CE/BZA) has demonstrated benefit in vulvar-vaginal atrophy (VVA, part of genitourinary syndrome of menopause) and the sexual function domain of the Menopause-specific Quality of Life (MENQOL) questionnaire. The study's objective was to determine the relationship of VVA symptoms and clinical parameters with MENQOL sexual functioning in postmenopausal women receiving VVA treatment. STUDY DESIGN: Post hoc analysis data were derived from the 12-week SMART-3 trial, which evaluated CE/BZA's effect on VVA in nonhysterectomized postmenopausal women (aged 40-65 years) experiencing one or more moderate to severe VVA symptoms (dryness, itching/irritation, pain with intercourse) and vaginal pH>5...
June 2017: Maturitas
https://www.readbyqxmd.com/read/28539165/drug-holidays-from-bisphosphonates-and-denosumab-in-postmenopausal-osteoporosis-emas-position-statement
#10
REVIEW
Panagiotis Anagnostis, Stavroula A Paschou, Gesthimani Mintziori, Iuliana Ceausu, Herman Depypere, Irene Lambrinoudaki, Alfred Mueck, Faustino R Pérez-López, Margaret Rees, Levent M Senturk, Tommaso Simoncini, John C Stevenson, Petra Stute, Florence A Trémollieres, Dimitrios G Goulis
BACKGROUND: Bisphosphonates and denosumab are used extensively in the treatment of postmenopausal osteoporosis. Despite their proven efficacy in the reduction of vertebral and non-vertebral fractures, their optimal duration of use has not been determined. The occurrence of adverse effects, such as osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF), has raised the issue of bisphosphonate or denosumab discontinuation ("drug holiday") after a certain treatment period. AIM: To assess the effect of bisphosphonate and denosumab discontinuation on fracture risk, as well as its possible benefits in reducing the risk of adverse effects...
July 2017: Maturitas
https://www.readbyqxmd.com/read/28539066/water-versus-land-based-treatment-for-postural-control-in-postmenopausal-osteoporotic-women-a-randomized-controlled-trial
#11
M Chaves Aveiro, M Arias Avila, V Santos Pereira-Baldon, A Santa Barbara Ceccatto Oliveira, K Gramani-Say, J Oishi, P Driusso
OBJECTIVE: To compare the effects of water-based and land-based physical therapy on postural control of older women with osteoporosis. METHODS: Thirty-six postmenopausal women with osteoporosis were allocated into two groups: land-based or water-based. Volunteers received 12 weeks of a supervised land-based or water-based physical therapy treatment. The outcome measure was postural control of the body during quiet standing on upright stance (eyes opened and closed), tandem and one-limb stance on a force plate...
May 25, 2017: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/28538603/a-systematic-review-of-the-exercise-effect-on-bone-health-the-importance-of-assessing-mechanical-loading-in-perimenopausal-and-postmenopausal-women
#12
Borja Sañudo, Moisés de Hoyo, Jesús Del Pozo-Cruz, Luis Carrasco, Borja Del Pozo-Cruz, Sergio Tejero, Elwyn Firth
OBJECTIVE: The aims of this systematic review were to determine the general effects of exercise on areal bone mineral density (BMD) in perimenopausal and postmenopausal women, and to provide information on the most suitable bone-loading exercise regimens that may improve bone health in this population group. METHODS: A computerized, systematic literature search was performed in the electronic databases PubMed, Web of Science, CINAHL, SPORTDiscus, and The Cochrane Library, from January 2005 to November 2015, to identify all randomized controlled trials related to exercise in perimenopausal and postmenopausal women...
May 22, 2017: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/28538602/pelvic-organ-prolapse-does-hormone-therapy-use-matter
#13
Erika J Wasenda, Ixora Kamisan Atan, Nishamini Subramaniam, Hans Peter Dietz
OBJECTIVE: To determine the effect of hormone therapy (HT) use on pelvic organ support. METHODS: A retrospective observational study involving postmenopausal women with pelvic floor dysfunction attending a tertiary urogynecology center between January 2012 and March 2015. All underwent a clinical examination including International Continence Society Pelvic Organ Prolapse Quantification and 4D translabial ultrasound imaging. Information on current or former use of systemic HT and current local estrogen use was collected...
May 22, 2017: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/28538396/effects-of-teriparatide-versus-alendronate-for-treatment-of-postmenopausal-osteoporosis-a-meta-analysis-of-randomized-controlled-trials
#14
Ya-Kang Wang, Si-Qing Qin, Tao Ma, Wei Song, Ren-Qi Jiang, Jian-Bin Guo, Kun Li, Yu-Min Zhang
OBJECTIVES: Osteoporosis remains a clinical challenge. Teriparatide is an anabolic drug and alendronate is an antiresorptive agent; both are used in the treatment of osteoporosis. Comprehensive reviews investigating the comparative safety and efficacy of teriparatide versus alendronate are scarce. Therefore, we conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the safety and efficacy of teriparatide versus alendronate for the treatment of postmenopausal osteoporosis...
May 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28538039/association-of-physical-activity-and-sitting-time-with-incident-colorectal-cancer-in-postmenopausal-women
#15
Anna M Gorczyca, Charles B Eaton, Michael J LaMonte, David O Garcia, Jeanne D Johnston, Ka He, Aurelian Bidulescu, Deborah Goodman, Erik Groessl, Dorothy Lane, Marcia L Stefanick, Polly Newcomb, Charles Mouton, Andrea K Chomistek
Findings from epidemiological studies have found that physical activity (PA) is associated with a lower risk of colorectal cancer (CRC). Recent studies have found an increased CRC risk with higher sitting time (ST); however, many studies did not include PA as a potential confounder. The objective of this project was to investigate the independent and combined associations of ST and PA with the risk of incident CRC, specifically colon and rectal cancer. Participants in the Women's Health Initiative Observational Study (n=74 870), 50-79 years of age self-reported ST and PA at baseline, years 3 and 6...
May 19, 2017: European Journal of Cancer Prevention
https://www.readbyqxmd.com/read/28537783/association-of-mild-to-moderate-reduction-in-glomerular-filtration-rate-with-subclinical-atherosclerosis-in-postmenopausal-women
#16
Florina Parv, Andrei Beceanu, Rodica Avram, Romulus Zorin Timar, Bogdan Timar, Florica Gadalean
BACKGROUND: Due to loss of hormonal protective effects, postmenopausal women have an increased cardiovascular (CV) risk. Chronic kidney disease (CKD) is a well-established risk factor for CV disease, but little is known whether mild-to-moderate kidney dysfunction is associated with atherosclerosis burden in the postmenopausal asymptomatic women. MATERIALS AND METHODS: Subclinical atherosclerosis was evaluated in 125 postmenopausal women with no clinical form of atherosclerosis, by carotid and femoral ultrasonography, ankle-brachial index (ABI), and flow-mediated dilation (FMD)...
May 24, 2017: Journal of Women's Health
https://www.readbyqxmd.com/read/28535898/treatment-of-postmenopausal-osteoporosis-a-literature-based-algorithm-for-use-in-the-public-health-care-system
#17
Ellen Luz Pereira Caires, Mailze Campos Bezerra, Ana Flávia Torquato de Araújo Junqueira, Sheila Márcia de Araújo Fontenele, Silvana Cristina de Albuquerque Andrade, Catarina Brasil d'Alva
Bisphosphonates are considered first-line agents in the treatment of postmenopausal osteoporosis based on extensive experience of use, safety, and proven efficacy in reducing vertebral, non-vertebral and femur fractures. However, post-marketing reports based on the treatment of millions of patients/year over lengthy periods of time have revealed the occurrence of initially unexpected adverse effects, such as osteonecrosis of the jaw and atypical femoral fracture, leading to the restriction of treatment duration with bisphosphonates by global regulatory agencies...
May 2017: Revista Brasileira de Reumatologia
https://www.readbyqxmd.com/read/28535365/leukocyte-telomere-length-in-postmenopausal-women
#18
Holly J Jones, Susan L Janson, Kathryn A Lee
OBJECTIVE: To compare leukocyte telomere length (LTL) by race and describe demographic, health, and psychosocial factors associated with LTL in postmenopausal women. DESIGN: Descriptive study with comparative analyses and correlations. SETTING: Data were collected at the University of California-San Francisco, San Francisco Clinical and Translational Science Institute. PARTICIPANTS: Thirty-nine African American and White postmenopausal women between 58 and 65 years of age (mean age = 61...
May 20, 2017: Journal of Obstetric, Gynecologic, and Neonatal Nursing: JOGNN
https://www.readbyqxmd.com/read/28535290/dietary-quality-and-ovarian-cancer-risk-in-african-american-women
#19
Bo Qin, Patricia G Moorman, Linda E Kelemen, Anthony J Alberg, Jill S Barnholtz-Sloan, Melissa Bondy, Michele L Cote, Ellen Funkhouser, Edward S Peters, Ann G Schwartz, Paul Terry, Joellen M Schildkraut, Elisa V Bandera
This study evaluated 3 index-based dietary patterns-Healthy Eating Index (HEI)-2005, HEI-2010, and Alternate Healthy Eating Index (AHEI)-2010-in relation to ovarian cancer risk in African-American women. The study was conducted among 415 ovarian cancer cases and 629 age- and site-matched controls of African-American descent recruited from the population-based African American Cancer Epidemiology Study. Multivariable unconditional logistic regression models were used to estimate odds ratios and 95% confidence intervals between quartiles of dietary quality indices and ovarian cancer risk, adjusting for potential confounders...
May 23, 2017: American Journal of Epidemiology
https://www.readbyqxmd.com/read/28534351/the-short-term-safety-of-adjuvant-paclitaxel-plus-trastuzumab-a-single-centre-experience
#20
Ozturk Ates, Veli Sunar, Alma Aslan, Fatih Karatas, Suleyman Sahin, Kadri Altundag
PURPOSE: HER2-amplified breast cancer (BC) has a poor prognosis. The combination of trastuzumab with chemotherapy in the adjuvant setting decreases recurrence and improves overall survival in HER2-positive BC. However, the role of adjuvant treatment in patients with HER2-amplified small BC without lymph node involvement is still under debate. The purpose of this study was to investigate the safety of adjuvant paclitaxel and trastuzumab (APT) in this group of patients. METHODS: A total of 87 operated early BC patients without lymph node involvement (N0) were treated with APT for 12 weeks followed by trastuzumab alone for a total of 9 months...
March 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
keyword
keyword
35339
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"